Table 1. Pre- and postoperative parameters of the study patients.
The information on the post-operative variables (Gleason sum, margin status, EPE, SVI and lymph node status) was assessed by pathologic examination of the surgical specimens immediately after surgery, and therefore, these parameters are considered as baseline covariates.
| Progression | Age (yrs) | PSA (ng/ml) | Clinical Stage | Gleason sum | 1EPE | Margin | 2SVI | Lymph node |
|---|---|---|---|---|---|---|---|---|
| Biochemical | Mean: | Mean: | T1c: 23 | 5 = 1 | (+) = 32 | (+) = 40 | (+) = 16 | (+) = 4 |
| recurrence* | 63.8± 5.9 | 11.5± 8.8 | (43.3%) | (1.9%) | (60.4%) | (75.5%) | (32%) | (7.6%) |
| (n = 53) | Median: | Median: | ||||||
| 65.5 | 8.9 | T2a: 10 | 6 = 4 | (−) = 21 | (−) = 13 | (−) = 37 | (−) = 49 | |
| Range: | Range: | (18.9%) | 7.5%) | (39.6%) | (26%) | (69.8%) | (92.5% | |
| 51 – 73 | 1.4 – 41.3 | |||||||
| T2b: 20 | 7 = 20 | |||||||
| (37.7%) | (37.7%) | |||||||
| 8 = 17 | ||||||||
| (32.1%) | ||||||||
| 9 = 11 | ||||||||
| (20.8%) | ||||||||
| No | Mean: | Mean: 6.6 | T1c: 32 | 4 = 1 | (+) = 7 | (+) = 14 | (+) = 2 | (+) = 0 |
| biochemical | 61.7± 7.1 | ± 3.0 | (64%) | (2%) | (14%) | (28%) | (4%) | (0%) |
| or clinical | Median: | Median: | ||||||
| recurrence | 63 | 6.2 | T2a: 10 | 5 = 4 | (−) = 43 | (−) = 36 | (−) = 48 | (−) = 50 |
| (n = 50) | Range: | Range: | (20%) | (8%) | (86%) | (72%) | (56%) | (100%0 |
| 41 – 75 | 0.5 – 15.5 | ≥T2b: 8 | ||||||
| (16%) | 6 = 12 | |||||||
| (24%) | ||||||||
| 7 = 29 | ||||||||
| (58%) | ||||||||
| 8 = 3 | ||||||||
| (6%) | ||||||||
| 9 = 1 | ||||||||
| (2%) | ||||||||
*
Out of the 53 patients who experienced biochemical recurrence, 47 recurred within 72 months and 29 recurred within 24 months.
1
EPE = extra-prostatic extension of tumor.
2
SVI = seminal vesicle invasion.
3
Three of the patients without recurrence had an unspecified T2 clinical stage.